Patrys Ltd (PAB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Patrys Ltd (PAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013562
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Patrys Ltd (Patrys) is a healthcare company that provides therapeutic products. The company offers product pipeline such as PAT-SC1 used for the treatment of gastric cancer; PAT-SM6, PAT-PA1, and PAT-LM1 used to treat multiple cancers. It develops natural human antibody-based therapeutic products for the treatment of cancer and many other diseases. Patrys’ pipeline consists of antibodies at different stages of early preclinical development and library, consists of discoveries stage of anti-cancer natural human antibodies. The company distributes its products in the US, Japan, Canada, Australia; and in different parts of Europe, and others. Patrys is headquartered in Melbourne, Victoria, Australia.

Patrys Ltd (PAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Patrys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Patrys Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Patrys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Patrys Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Patrys Enters into Licensing Agreement with Yale University 11
Patrys Enters into Licensing Agreement with Yale University 12
Hefei Co-source to Enter into Licensing Agreement with Patrys for PAT-SC1 13
Equity Offering 14
Patrys Completes Private Placement Of Shares For US$0.8 Million 14
Patrys Completes Rights Offering Of Shares 15
Patrys Completes Second Tranche Of Private Placement Of Shares For US$1 Million 16
Patrys Announces Rights Offering Of Shares For US$0.81 Million 18
Patrys Completed Private Placement Of Common Stock For US$3.48 Million 19
Patrys Ltd – Key Competitors 20
Patrys Ltd – Key Employees 21
Patrys Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Product News 23
03/31/2016: Publication Highlights Role of Patrys’ DNA-Damaging Antibody 5-C6 in Cancer 23
03/31/2016: Publication Highlights Role of Patrys’ DNA-Damaging Antibody Deoxymab in Cancer 24
Clinical Trials 25
Sep 14, 2017: Patrys: PAT-DX1 Active in Pre-clinical Cancer Models 25
Apr 19, 2017: Deoxymab 3E10 lead candidate confirmed 26
Other Significant Developments 27
May 01, 2017: Patrys provides Finance Update 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Patrys Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Patrys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Patrys Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Patrys Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Patrys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Patrys Enters into Licensing Agreement with Yale University 11
Patrys Enters into Licensing Agreement with Yale University 12
Hefei Co-source to Enter into Licensing Agreement with Patrys for PAT-SC1 13
Patrys Completes Private Placement Of Shares For US$0.8 Million 14
Patrys Completes Rights Offering Of Shares 15
Patrys Completes Second Tranche Of Private Placement Of Shares For US$1 Million 16
Patrys Announces Rights Offering Of Shares For US$0.81 Million 18
Patrys Completed Private Placement Of Common Stock For US$3.48 Million 19
Patrys Ltd, Key Competitors 20
Patrys Ltd, Key Employees 21
Patrys Ltd, Subsidiaries 22

★海外企業調査レポート[Patrys Ltd (PAB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Empresa Electricidad del Peru SA (ELECPBC1):企業の財務・戦略的SWOT分析
    Empresa Electricidad del Peru SA (ELECPBC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • PledPharma AB (PLED):企業の財務・戦略的SWOT分析
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. PledOX drug is used to prevent chemotherapy-induced side effects for colorectal …
  • Hexcel Corp (HXL):企業の財務・戦略的SWOT分析
    Hexcel Corp (HXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Greensmith Energy Management Systems LLC:企業の戦略的SWOT分析
    Greensmith Energy Management Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Nephros Inc (NEPH)-医療機器分野:企業M&A・提携分析
    Summary Nephros Inc (Nephros) is medical device company that develops and markets filtration products. The company offers infection control filters, dialysis ultrafilters, and hemodia filtration systems. Its dialysis ultrafilters are intended to be used to filter water and bicarbonate concentrate us …
  • Baoye Group Company Limited:企業の戦略・SWOT・財務情報
    Baoye Group Company Limited - Strategy, SWOT and Corporate Finance Report Summary Baoye Group Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • icapital biz Berhad:企業の戦略・SWOT・財務情報
    icapital biz Berhad - Strategy, SWOT and Corporate Finance Report Summary icapital biz Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Dana Incorporated:企業のM&A・事業提携・投資動向
    Dana Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dana Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Showa Denko KK (4004):企業の財務・戦略的SWOT分析
    Showa Denko KK (4004) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Tarsa Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tarsa Therapeutics Inc (Tarsa) is a developer of therapies for the treatment and prevention of osteoporosis and other bone related diseases. The company develops calcitonin tablet TBRIA, an oral formulation of calcitonin, a peptide hormone that inhibits bone resorption, which is used for the …
  • VeriFone Systems Inc:企業の戦略・SWOT・財務分析
    VeriFone Systems Inc - Strategy, SWOT and Corporate Finance Report Summary VeriFone Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Chiesi USA Inc:企業の戦略的SWOT分析
    Chiesi USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Reply S.p.A. (REY):企業の財務・戦略的SWOT分析
    Reply S.p.A. (REY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Indianola Municipal Utilities:発電所・企業SWOT分析
    Indianola Municipal Utilities - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Intershop Communications AG (ISH2):企業の財務・戦略的SWOT分析
    Summary Intershop Communications AG (Intershop), formerly NetConsult GmbH, is an information technology company that develops and offers integrated e-commerce solutions. The company provides services such as omni-channel management, experience management, product information management, marketing an …
  • Aeris Resources Limited:企業の戦略・SWOT・財務分析
    Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Crinetics Pharmaceuticals Inc (CRNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Crinetics Pharmaceuticals Inc (Crinetics) is a developer of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products include neuropeptides and their receptors, orally-available somatostatin agon …
  • Cerenis Therapeutics Holding SA (CEREN):企業の財務・戦略的SWOT分析
    Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic …
  • The Hackett Group, Inc.:企業の戦略・SWOT・財務分析
    The Hackett Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Hackett Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • FLX Bio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary FLX Bio Inc (FLX Bio) is an immuno-oncology company that discovers and develops novel immuno-oncology agents. The company develops lead oral small molecule compound, FLX475, blocks a receptor called CCR4, found on nearly all human Treg cells that binds to secreted factors made in the tumor m …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆